This study is in progress, not accepting new patients
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Multiple Sclerosis, Relapsing-RemittingSclerosisMultiple SclerosisOcrelizumab
Lead Scientist at UCSF
- Emmanuelle Waubant
Dr Waubant trained as a neurologist in Toulouse, France. She continued her training as a neuroimmunology fellow in Dr Stephen Hauser’s UCSF laboratory, focusing on matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP), and their role in migration of lymphocytes through equivalents of the blood-brain barrier.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Genentech, Inc.
- Phase 3
- Study Type
- Last Updated